Eritadenine

Eritadenine

SCHEMBL308656

Nc1ncnc2c1ncn2C[C@@H](O)[C@@H](O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.76
AHCY P23526 7/20 0.68
ADORA2A P29274 7/20 0.64
ADORA1 P30542 4/20 0.64
EGFR P00533 1/20 0.54
PI4KA P42356 2/20 0.52
PI4K2B Q8TCG2 2/20 0.52
PI4K2A Q9BTU6 2/20 0.52
PI4KB Q9UBF8 2/20 0.52
CYP3A4 P08684 1/20 0.52
ADCY5 O95622 2/20 0.50
ADORA2B P29275 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eritadenine SCHEMBL3076264 1.00 ALDH1A1 (0.76) ALDH1A1AHCYADORA2AADORA1EGFR
Eritadenine SCHEMBL27715791 1.00 ALDH1A1 (0.76) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL2049963 0.86 ALDH1A1 (1.00) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL2049962 0.86 ALDH1A1 (1.00) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL2049965 0.86 ALDH1A1 (1.00) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL2270408 0.83 ALDH1A1 (0.75) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL10683911 0.83 ALDH1A1 (0.75) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL6532875 0.82 ALDH1A1 (0.73) ALDH1A1AHCYADORA2AADORA1EGFR
SCHEMBL11474105 0.82 AHCY (0.76) ALDH1A1AHCYADORA2AADORA1PI4KA
SCHEMBL16603993 0.81 AHCY (0.85) ALDH1A1AHCYADORA2AADORA1PI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116369504-B Lentinus edodes extract rich in lentinula edodes purine, lentinula edodes residue proteolytic peptide liquid, and preparation method and application thereof 湖北浩伟科技股份有限公司 2024-10-01 CN claimed
CN-116369504-A Lentinus edodes extract rich in lentinula edodes purine, lentinula edodes residue proteolytic peptide liquid, and preparation method and application thereof 湖北省农业科学院农产品加工与核农技术研究所 2023-07-04 CN claimed
EP-4101291-A1 METHOD FOR PREPARING VITAMIN D DERIVED FROM SHIITAKE MUSHROOMS Kim, Jeong Ok (KR) 2022-12-14 EP claimed
CN-115066174-A Preparation method of vitamin D from shiitake mushroom 金正玉 2022-09-16 CN claimed
CN-109511939-A A kind of baked chicken flavor essence of allotment type Mo Gu and preparation method thereof 天津春发生物科技集团有限公司 2019-03-26 CN claimed
CN-108669177-A A kind of lentinacin cake and preparation method thereof 友臣(福建)食品有限公司 2018-10-19 CN claimed
CN-107232562-A A kind of compressed type composite beef flour soup and preparation method thereof 尹连花 2017-10-10 CN claimed
CN-105136964-B A kind of method for detecting lentinacin and mushroom alcohol 上海市农业科学院 2017-09-26 CN claimed
US-20160367645-A1 LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2016-12-22 US claimed
CN-106070501-A A kind of precious mushroom moon cake and preparation method thereof 开平健之源保健食品有限公司 2016-11-09 CN claimed
CN-1089086-C Luminandide medicine MILLS RANDELL L (US) 2002-08-14 CN claimed
US-6365186-B1 ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT GELTEX PHARMACEUTICALS, INC. 2002-04-02 US claimed
WO-2001037680-A1 FOOD COMPOSITIONS AND METHODS OF PREPARING THE SAME ERITOCAP OY (FI) 2001-05-31 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000069445-A1 COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0414730-B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug MILLS RANDELL L (US) 1999-12-15 EP claimed
CN-1178122-A Multifunctional nutrient liquid for banting and preventing cancers QUEYUAN INTERNATIONAL BIOLOG E (CN) 1998-04-08 CN claimed
CN-1122206-A Producing method for pine kernel and xianggu mushroom soy sauce and its product SUN XIYUN (CN) 1996-05-15 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367645-A1 LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES LIPC, PNLIP, LIPA ALDH1A1 1049/4885AHCY 1101/4885ADORA2A 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.